LKKTETQ is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Although most species of psilocybin-containing mushrooms bruise blue when handled or damaged due to the oxidization of phenolic compounds, this reaction is not a definitive method of identification or determining a mushroom's potency.
Workplace exposure can be at a high concentration for the duration of a shift, and thus short-term, whereas exposure outside of work is at low concentration and long-term. For instance, the concentration of worker exposure from extrusion 3D printers is orders of magnitude higher than the general population (e.g., 4×1010 particles per cubic meter [m3] versus 50 particles per m3 in the general environment). The main route of workplace exposure is acute inhalation. Plastics are extensively used in the construction and renovation industry. Airborne microplastic dust is produced during renovation, building, bridge and road reconstruction. High chronic exposure to aerosolized MNPs also occurs in the synthetic textile industry, the flocking industry, and the plastics industry, especially in vinyl chloride and polyvinyl chloride (PVC) manufacturers. In manufacturing, there is risk of exposure to both intentionally and incidentally generated MNPs. For instance, MNPs are intentionally generated during 3D printing but can also be incidentally generated due to mechanical or environmental degradation, or through industrial processes such as plastic manufacturing (heating and chemical condensation).
Photolithography Electron-beam lithography X-ray lithography Extreme ultraviolet lithography Light coupling nanolithography Scanning probe microscope Nanoimprint lithography Dip-Pen nanolithography Soft lithography Each nanolithography technique has varying factors of the resolution, time consumption, and cost. There are three basic methods used by nanolithography. One involves using a resist material that acts as a "mask", known as photoresists, to cover and protect the areas of the surface that are intended to be smooth. The uncovered portions can now be etched away, with the protective material acting as a stencil. The second method involves directly carving the desired pattern. Etching may involve using a beam of quantum particles, such as electrons or light, or chemical methods such as oxidation or Self-assembled monolayers. The third method places the desired pattern directly on the surface, producing a final product that is ultimately a few nanometers thicker than the original surface. To visualize the surface to be fabricated, the surface must be visualized by a nano-resolution microscope, which includes the scanning probe microscopy and the atomic force microscope. Both microscopes can also be engaged in processing the final product.
Obsessive–compulsive disorder (OCD), which happens to be its only US FDATooltip Food and Drug Administration-labeled indication. Other regulatory agencies (such as the TGA of Australia and the MHRA of the UK) have also approved clomipramine for this indication. A 2024 systematic review found that clomipramine is also effective in managing OCD in pediatric population. Major depressive disorder (MDD), a popular off-label use in the US. It is approved by the Australian TGA and the United Kingdom MHRA for this indication. In Japan it is also approved for depression. Some have suggested the possible superior efficacy of clomipramine compared to other antidepressants in the treatment of MDD, especially the more severe, although at the current time the evidence may be insufficient to more fully substantiate this claim. As-with other tricyclic antidepressants, the antidepressant response specifically may be augmented, including in treatment-resistant cases, with triiodothyronine, at a dosage of 50 mcg. In the case of clomipramine specifically, this may also be the case with OCD.
Met-enkephalin, also known as metenkefalin (INN), sometimes referred to as opioid growth factor (OGF), is a naturally occurring, endogenous opioid peptide that has opioid effects of a relatively short duration. It is one of the two forms of enkephalin, the other being leu-enkephalin. The enkephalins are considered to be the primary endogenous ligands of the δ-opioid receptor, due to their high potency and selectivity for the site over the other endogenous opioids.
Sources: en.wikipedia.org
== History == The first acknowledged case of obesity-related non-alcoholic fatty liver was observed in 1952 by Samuel Zelman. Zelman started investigating after observing a fatty liver in a hospital employee who drank more than twenty bottles of Coca-Cola a day. He then went on to design a trial for a year and a half on 20 people with obesity who did not have alcohol use disorder, finding that about half of them had substantially fatty livers. Fatty liver was, however, linked to diabetes since at least 1784 — an observation picked up again in the 1930s. Studies in experimental animals implicated choline inadequacy in the 1920s and excess sugar consumption in 1949. The name "non-alcoholic steatohepatitis" (NASH) was later defined in 1980 by Jurgen Ludwig and his colleagues from the Mayo Clinic to raise awareness of the existence of this pathology, as similar reports previously were dismissed as "patients' lies". This paper was mostly ignored at the time but eventually came to be seen as a landmark paper, and starting in the mid-1990s, the condition began to be intensively studied, with a series of international meetings being held on the topic since 1998. The broader NAFLD term started to be used around 2002. Diagnostic criteria began to be worked out, and in 2005 the Pathology Committee of the NIH NASH Clinical Research Network proposed the NAS scoring system. In 2023, a global consensus panel composed mostly of hepatology researchers and clinicians recommended a change of name to metabolic dysfunction–associated steatotic liver disease (MASLD).
==== Effects in preclinical studies ==== Trazodone shows antidepressant- and anxiolytic-like effects in animals. However, it shows differences from certain other antidepressants, like the tricyclic antidepressants, in animals. For example, it does not reverse the behavioral effects of the monoamine depleting agent reserpine and does not potentiate the effects of amphetamine or levodopa. Similarly to antipsychotics, trazodone reduces spontaneous motor activity, spontaneous and elicited aggressive behavior, and exploratory behavior, among other effects. In addition, trazodone diminishes amphetamine-induced locomotor hyperactivity, although it does not inhibit apomorphine- or amphetamine-induced stereotypy. On the other hand, unlike antipsychotics, trazodone does not produce catalepsy, although it can do so at sufficiently high doses. Activation of the serotonin 5-HT2A receptor enhances striatal dopaminergic neurotransmission, while stimulation of the serotonin 5-HT2C receptor inhibits striatal dopaminergic neurotransmission. Trazodone is both a serotonin 5-HT2A and 5-HT2C receptor antagonist, but has about 15-fold greater potency as an antagonist of the 5-HT2A receptor relative to the 5-HT2C receptor. In addition, at higher doses, trazodone acts as a dopamine D2 receptor antagonist in animals. As a result of the preceding actions, trazodone may inhibit striatal dopaminergic neurotransmission. This may underlie exacerbation of parkinsonism seen in marmosets and in human case reports.
=== Latin America and Caribbean === Gustavo Petro, President of Colombia, initially suggested that any attack on Venezuela would equate to an attack on Latin America and the Caribbean, and thus Colombia's armed forces could support Venezuela; he later moderated his position. On 23 September, he addressed the UN General Assembly to call for a "criminal process" to be opened against Donald Trump for US strikes in the Caribbean. Colombia convened an extraordinary virtual meeting of the Community of Latin American and Caribbean States in September 2025, which concluded with an expression of "deep concern" over foreign intervention in the region. Over Guatemala's objection that procedures were not followed, the group issued a statement saying the region must remain a "Zone of Peace" based on "... the prohibition of the threat or use of force, the peaceful settlement of disputes, the promotion of dialogue and multilateralism, unrestricted respect for sovereignty and territorial integrity, non-interference in the internal affairs of States, and the inalienable right of peoples to self-determination." Guatemala's president Bernardo Arévalo said Guatemala was included in the list of 21 countries (of the 33 members) approving the text, although it did not sign, nor did Ecuador, Peru, Costa Rica, and El Salvador. In August, when the initial three ships were deployed, Prime Minister of Trinidad and Tobago Kamla Persad-Bissessar offered the US military access to her nation for the US to protect Guyana amid the Guyana–Venezuela crisis.
SIRIUS can search in databases of hypothetical structures. This could be for example interesting for finding derivatives. The predicted molecular fingerprint offers structural information about, e.g., substructures. CANOPUS predicts the compound classes of a molecule without searching in a database. MSNovelist de novo generates candidate structures from the predicted molecular fingerprint.
However, unlike special interest groups these committees have come under some oversight regulation and are required to make formal records available to the public. As of 2002, about 1,000 of these advisory committees were described in the FACA searchable database.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.